Prof. PeptideProf. Peptide

Everything you need for peptide research, in one place

Prof. Peptide is an independent research library of peptide profiles, vendor reviews, price comparisons across all vendors, and verified discount codes.

Plus a precision dosage calculator and an all-in-one protocol tracker app.

71

Peptide profiles

75

Compounds compared

104

Verified discount codes

100%

Independent research

Prof. Peptide provides peptide research for educational purposes only. Nothing on this site constitutes medical advice or endorses human use of research peptides.

Latest News

View all news

October 17, 2026

FDA Again Says Retatrutide Is a Drug; the Seventh Circuit Asks Whether Lilly Can Appeal at All

On October 2, 2026 the FDA issued its decision on remand in Lilly v. Kennedy and again concluded that retatrutide, built on a 39-alpha-amino-acid chain, is neither a protein nor an analogous product, so it is not a biological product. Meanwhile the Seventh Circuit, after the September 24 argument, ordered briefing on whether Lilly may appeal a remand order at all; both sides filed on October 8. What the FDA decided, what each side told the court, and what remains open.

Read more →

October 17, 2026

TRIUMPH-1 Is Now in the NEJM: Retatrutide's 80-Week Obesity Results

The phase 3 TRIUMPH-1 trial of retatrutide is now peer-reviewed. The New England Journal of Medicine paper (September 29, 2026) reports 80-week outcomes in 2,339 adults with obesity: mean weight change of -17.6%, -23.7% and -25.0% at 4, 9 and 12 mg versus -3.9% with placebo, plus knee osteoarthritis pain and sleep apnea results. The figures as published, what the abstract says about adverse events, and how they differ from May's company release.

Read more →

October 17, 2026

TRIUMPH-2: Retatrutide in Type 2 Diabetes and Obesity, With the Adverse Events

Lilly's phase 3 TRIUMPH-2 trial of retatrutide in 1,152 adults with type 2 diabetes and obesity was presented at EASD on September 29, 2026 and published in The Lancet. Weight change at 80 weeks was -11.9%, -16.8% and -18.8% versus -5.1% on the journal's treatment-regimen estimand, and -12.7%, -19.1% and -20.8% on Lilly's efficacy estimand. With them: diarrhoea, nausea, hypotension, dysesthesia and discontinuation rates.

Read more →

Everything a researcher needs

From peptide mechanisms to reconstitution math — Prof. Peptide covers it all, clearly and credibly.

Why Prof. Peptide

Built for researchers

Most peptide sites exist to sell products. Prof. Peptide exists to educate. We're independent, ad-light, and committed to presenting research accurately — including limitations and unknowns.

  • ✓Content is editorially independent and research-driven
  • ✓Every peptide profile cites primary research literature
  • ✓Calculator math is transparent and peer-reviewable
  • ✓Discount codes are manually verified before publishing

Now on iOS

The all-in-one peptide tracker

Log doses, see estimated levels, calculate reconstitution, and search 70+ peptides by name or brand — all in one private iOS app.

Get the App

Don't overpay for peptides.

Let us do the research and find the best deals for you.